Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.76 USD
+0.86 (1.63%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $40.81, signifying a -0.39% move from its prior day's close.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
by Zacks Equity Research
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Replimune (REPL) Gains on Positive Data From Melanoma Study
by Zacks Equity Research
Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
by Zacks Equity Research
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $41.77, moving +1.65% from the previous trading session.
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
by Zacks Equity Research
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
Walmart Earnings & the State of the Consumer
by Sheraz Mian
We discuss what Walmart's blockbuster results tell us about the health of the consumer economy.
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
by Ekta Bagri
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
A Look at Pharma ETFs Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
by Zacks Equity Research
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.